Advances in Liquid Biopsy Platforms

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE depicts trends across liquid biopsy platforms. The advent of novel antibody-based and targeted small molecule therapies have greatly improved the management of cancer disease. However, there is a growing need for robust monitoring platforms for enhanced assessment of diseases progression and treatment monitoring in cancer patients. Lung cancer clinical trials using liquid biopsy platforms are depicted along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisi

Table of Contents

Advances in Liquid Biopsy PlatformsRecent Innovations in Liquid Biopsy PlatformsNovel Liquid Biopsy Platform for Cancer MonitoringAnalyzing Free-floating Genome for Early Cancer DetectionCirculating Tumor DNA for Monitoring Chronic Lymphocytic LeukemiaExtracellular Vesicle Isolation Technology for Liquid Biopsy ApplicationsClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.